Fennec Pharmaceuticals Inc (FENC)

$6.25 +0.32 (5.40%)
Market Cap 200.30M
Revenue (ttm) 44.64M
Net Income (ttm) -9.74M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 21.16
Profit Margin -21.82%
Debt to Equity Ratio 0.00
Volume 193,733
Avg Vol 175,928
Day's Range N/A - N/A
Shares Out 34.48M
Stochastic %K 30%
Beta 0.93
Analysts Strong Sell
Price Target $15.14

Company Profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium...

Industry: Biotechnology
Sector: Healthcare
Phone: 919 636 4530
Address:
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, United States
BioTechHealthX
BioTechHealthX Apr. 12 at 2:47 AM
$CRDL $CTMX $FENC $INO $TERN These biotech microcap stocks are flying under the radar but showing massive growth potential. Discover 10 high-risk, high-reward biotech plays that could deliver explosive returns as clinical catalysts approach. https://biotechhealthx.com/biotech-news/top-10-best-biotech-microcap-stocks-that-could-explode-10x-in-2026/
0 · Reply
Eaglelanded
Eaglelanded Apr. 10 at 8:50 PM
$FENC horribly run - what a pity - such a great opportunity
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:12 PM
$FENC says the University of Arizona Cancer Center is launching an investigator-sponsored PEDMARK study in AYA and adult cisplatin patients.
0 · Reply
BioTuesdays
BioTuesdays Apr. 7 at 6:01 PM
$FENC has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection, in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. https://biotuesdays.com/2026/04/07/uacc-initiates-study-of-fennecs-pedmark-for-aya-and-adult-cancers/
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 3 at 12:40 AM
$FENC Share Price: $6.41 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.11 – $2.57 Potential Upside: 73% ROI Time to Expiration: 231 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 29 at 3:03 PM
$FENC Fennec Pharmaceuticals stands out in biotech by already generating revenue. With a niche oncology product and growing adoption, FENC stock is catching investor attention. https://biotechhealthx.com/biotech-news/is-it-a-good-decision-to-buy-fennec-pharmaceuticals-fenc-shares/
0 · Reply
Stanley229
Stanley229 Mar. 27 at 9:42 AM
$FENC
0 · Reply
Golfskier
Golfskier Mar. 24 at 3:58 PM
$FENC Well, I guess light on revs and the burn was up...right back into the "show me" camp.
0 · Reply
ap20
ap20 Mar. 24 at 2:46 PM
$FENC Why is this down today? I’m clueless, as usual.
1 · Reply
OpenOutcrier
OpenOutcrier Mar. 24 at 12:44 PM
$FENC (-6.0% pre) Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://ooc.bz/l/97013
0 · Reply
Latest News on FENC
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

Apr 7, 2026, 7:03 AM EDT - 7 days ago

Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2026, 6:00 AM EDT - 14 days ago

Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 1:20 PM EDT - 21 days ago

Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 24, 2026, 7:00 AM EDT - 21 days ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Mar 23, 2026, 4:40 PM EDT - 22 days ago

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Mar 18, 2026, 7:08 AM EDT - 27 days ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Mar 4, 2026, 7:05 AM EST - 5 weeks ago

Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

Dec 26, 2025, 5:44 PM EST - 3 months ago

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

Dec 9, 2025, 7:00 AM EST - 4 months ago

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Dec 2, 2025, 7:01 AM EST - 4 months ago

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 5:59 AM EST - 4 months ago

Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

Nov 17, 2025, 4:15 PM EST - 5 months ago

Fennec Pharmaceuticals Announces Closing of Offering of Common Shares

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

Nov 13, 2025, 11:11 PM EST - 5 months ago

Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

Nov 13, 2025, 11:07 PM EST - 5 months ago

Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

Nov 13, 2025, 4:08 PM EST - 5 months ago

Fennec Pharmaceuticals Announces Proposed Offering of Common Shares

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

Aug 14, 2025, 6:08 AM EDT - 8 months ago

Fennec Pharmaceuticals Reports Second Quarter 2025 Financial Results And Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

Aug 11, 2025, 7:12 AM EDT - 8 months ago

Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025

Fennec Announces Results of Annual Meeting

Jun 3, 2025, 4:31 PM EDT - 11 months ago

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

May 8, 2025, 4:17 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 10, 2025, 6:03 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Mar 6, 2025, 4:22 PM EST - 1 year ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Feb 7, 2025, 7:00 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Dec 20, 2024, 6:16 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Dec 19, 2024, 6:13 AM EST - 1 year ago

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Dec 12, 2024, 7:01 AM EST - 1 year ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 6:13 AM EST - 1 year ago

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Oct 31, 2024, 6:23 AM EDT - 1 year ago

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Oct 28, 2024, 6:23 AM EDT - 1 year ago

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 5, 2024, 6:56 AM EDT - 1 year ago

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 13, 2024, 6:05 AM EDT - 1 year ago

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Aug 6, 2024, 4:31 PM EDT - 1 year ago

Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Aug 5, 2024, 6:26 AM EDT - 1 year ago

Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director

Fennec Pharmaceuticals Announces Management Change

Jul 1, 2024, 6:00 AM EDT - 1 year ago

Fennec Pharmaceuticals Announces Management Change

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 6:03 AM EDT - 2 years ago

Fennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

May 7, 2024, 6:15 PM EDT - 2 years ago

Fennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Mar 21, 2024, 6:00 AM EDT - 2 years ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Mar 19, 2024, 6:01 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Mar 17, 2024, 9:00 PM EDT - 2 years ago

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

Feb 29, 2024, 7:04 AM EST - 2 years ago

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Feb 1, 2024, 5:55 AM EST - 2 years ago

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

Fennec Announces Incremental $5 Million Investment from Petrichor

Dec 5, 2023, 5:55 AM EST - 2 years ago

Fennec Announces Incremental $5 Million Investment from Petrichor

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Nov 6, 2023, 5:59 AM EST - 2 years ago

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 30, 2023, 6:45 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Aug 3, 2023, 5:59 AM EDT - 2 years ago

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Jul 31, 2023, 5:30 AM EDT - 2 years ago

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Jun 6, 2023, 5:44 AM EDT - 3 years ago

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 11, 2023, 6:01 AM EDT - 3 years ago

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

May 8, 2023, 6:15 AM EDT - 3 years ago

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Mar 31, 2023, 8:03 AM EDT - 3 years ago

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Mar 30, 2023, 5:55 AM EDT - 3 years ago

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

BioTechHealthX
BioTechHealthX Apr. 12 at 2:47 AM
$CRDL $CTMX $FENC $INO $TERN These biotech microcap stocks are flying under the radar but showing massive growth potential. Discover 10 high-risk, high-reward biotech plays that could deliver explosive returns as clinical catalysts approach. https://biotechhealthx.com/biotech-news/top-10-best-biotech-microcap-stocks-that-could-explode-10x-in-2026/
0 · Reply
Eaglelanded
Eaglelanded Apr. 10 at 8:50 PM
$FENC horribly run - what a pity - such a great opportunity
0 · Reply
focafoca99
focafoca99 Apr. 7 at 9:12 PM
$FENC says the University of Arizona Cancer Center is launching an investigator-sponsored PEDMARK study in AYA and adult cisplatin patients.
0 · Reply
BioTuesdays
BioTuesdays Apr. 7 at 6:01 PM
$FENC has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection, in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. https://biotuesdays.com/2026/04/07/uacc-initiates-study-of-fennecs-pedmark-for-aya-and-adult-cancers/
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 3 at 12:40 AM
$FENC Share Price: $6.41 Contract Selected: Nov 20, 2026 $10 Calls Buy Zone: $1.15 – $1.42 Target Zone: $2.11 – $2.57 Potential Upside: 73% ROI Time to Expiration: 231 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 29 at 3:03 PM
$FENC Fennec Pharmaceuticals stands out in biotech by already generating revenue. With a niche oncology product and growing adoption, FENC stock is catching investor attention. https://biotechhealthx.com/biotech-news/is-it-a-good-decision-to-buy-fennec-pharmaceuticals-fenc-shares/
0 · Reply
Stanley229
Stanley229 Mar. 27 at 9:42 AM
$FENC
0 · Reply
Golfskier
Golfskier Mar. 24 at 3:58 PM
$FENC Well, I guess light on revs and the burn was up...right back into the "show me" camp.
0 · Reply
ap20
ap20 Mar. 24 at 2:46 PM
$FENC Why is this down today? I’m clueless, as usual.
1 · Reply
OpenOutcrier
OpenOutcrier Mar. 24 at 12:44 PM
$FENC (-6.0% pre) Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update https://ooc.bz/l/97013
0 · Reply
ap20
ap20 Mar. 24 at 12:24 PM
$FENC Great solid growth. Nice q.
0 · Reply
deedeethegenius
deedeethegenius Mar. 23 at 7:11 PM
$FENC $CNXC ideas
0 · Reply
JackCampbell
JackCampbell Mar. 18 at 2:42 PM
$FENC https://finance.yahoo.com/news/fennec-pharmaceuticals-report-full-fourth-110800755.html
0 · Reply
focafoca99
focafoca99 Mar. 17 at 6:33 AM
$FENC settling the Cipla fight and landing a license deal with Cipla/Cipla USA on the same day is a lot cleaner than the market probably expected.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 1:40 PM
$FENC RSI: 30.00, MACD: -0.0596 Vol: 0.46, MA20: 8.34, MA50: 7.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Stanley229
Stanley229 Mar. 2 at 5:52 PM
$FENC why is FENC on its way down? Are we not expecting good Q4 results next week?
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 27 at 4:02 AM
$FENC RSI: 70.56, MACD: 0.3039 Vol: 0.52, MA20: 8.25, MA50: 7.89 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
prismmarketview
prismmarketview Feb. 26 at 5:56 PM
Investing in Innovation during Rare Disease Day 2026 $LRMR $ZVRA $FENC $RZLT $IRD Investing in Innovation during Rare Disease Day 2026 https://prismmarketview.com/investing-in-innovation-during-rare-disease-day-2026/
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 22 at 3:06 AM
$FENC Current Stock Price: $8.72 Contracts to trade: $10.0 FENC Mar 20 2026 Call Entry: $0.45 Exit: $0.72 ROI: 61% Hold ~23 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 20 at 1:25 PM
$FENC (+2.1% pre) Fennec presents real world data on PEDMARK for head and neck cancer patients https://ooc.bz/l/94023
0 · Reply
JackCampbell
JackCampbell Feb. 12 at 2:52 PM
$FENC Fennec PharmaceuticalsInc. (NASDAQ: FENC) was started with a Buy rating at B. Riley with a $16 target price.
0 · Reply
G101SPM
G101SPM Feb. 12 at 12:26 PM
$FENC $7.90 bid. Holding long position https://stocktwits.com/G101SPM/message/603287700 BRIEF: Fennec Pharmaceuticals (FENC) initiated with a Buy at B. Riley, tgt $16
1 · Reply